Healthcare CRO Services Market Report 2026

The healthcare cro services market size has grown strongly in recent years. It will grow from $66.77 billion in 2025 to $72.87 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing number of clinical trials globally, rising research and development expenditure, complexity of regulatory approval processes, expansion of pharmaceutical pipelines, availability of specialized cro expertise.

The healthcare cro services market size is expected to see strong growth in the next few years. It will grow to $105.23 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to increasing adoption of decentralized clinical trials, rising demand for faster drug development timelines, expansion of biologics and biosimilar research, growing focus on real-world evidence generation, increasing investments in precision medicine research. Major trends in the forecast period include increasing outsourcing of clinical trial operations, rising adoption of data-driven trial management, growing demand for end-to-end cro services, expansion of decentralized and virtual clinical trials, enhanced focus on regulatory compliance support.

The increasing number of clinical trials is expected to drive the growth of the healthcare CRO services market in the coming years. A clinical trial is a scientific study involving human participants to evaluate the safety and efficacy of new medical interventions, including drugs, therapies, devices, or procedures. Contract research organizations (CROs) play a critical role in this process by offering a wide range of services that help pharmaceutical and biotechnology companies design, conduct, and manage their studies efficiently. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the total number of clinical trials initiated in the UK increased from 411 in 2022 to 426 in 2023. This growth in clinical trials is driving the expansion of the healthcare CRO services market.

Major companies in the healthcare CRO services market are increasingly forming strategic partnerships to provide advanced proteomics CRO services to biopharmaceutical and biomarker clients globally. Strategic partnerships involve companies leveraging each other’s strengths and resources to achieve mutual benefits. For instance, in January 2023, Bruker Corporation, a US-based scientific instrument manufacturer, partnered with Biognosys AG, a Switzerland-based healthcare CRO services provider. This collaboration is expected to generate unique synergies by combining Biognosys’ proprietary proteomics services, software, and kits with Bruker’s innovative timsTOF platform. As a result, Biognosys will establish its first laboratory for advanced proteomics CRO services in the United States.

In May 2023, Elliott Investment Management L.P., a US-based investment management firm, Patient Square Capital, a US-based capital market company, and Veritas Capital Fund Management LLC, a US-based quantitative and systematic asset management firm, jointly acquired Syneos Health Inc. for $7.1 billion. Through this acquisition, the consortium aims to expand its portfolio by incorporating Syneos Health’s expertise in healthcare CRO services. Syneos Health Inc. is a US-based company that provides healthcare contract research organization services.

Major companies operating in the healthcare cro services market are Laboratory Corporation of America Holdings., IQVIA Inc., Icon Plc., PPD Inc., Wuxi Apptec Co. Ltd., Syneos Health Inc., Parexel International Corporation, Charles River Laboratories International Inc., Covance Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., BioClinica Inc., Chiltern International Ltd., Evotec SE, PSI CRO AG, Premier Research Group Ltd., Worldwide Clinical Trials Inc., Caidya, BioTelemetry Inc., Syngene International Limited, Novotech CRO, Celerion, GVK Biosciences Private Limited, Synteract Inc., Veristat LLC., ACM Global Laboratories, ClinTec Luxembourg SA, Clinlogix LLC.

North America was the largest region in the healthcare CRO services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the healthcare cro services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the healthcare cro services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the healthcare CRO services market by increasing costs of imported laboratory equipment, clinical trial supplies, data management systems, and specialized research instruments. Pharmaceutical and biotechnology sponsors in North America and Europe are most affected due to cross-border sourcing of trial materials, while Asia-Pacific faces cost pressure on laboratory infrastructure expansion. These tariffs are increasing operational expenses and trial execution costs. At the same time, they are encouraging regional CRO partnerships, localized laboratory investments, and optimization of digital and remote trial methodologies.

The healthcare cro services market research report is one of a series of new reports that provides healthcare cro services market statistics, including healthcare cro services industry global market size, regional shares, competitors with a healthcare cro services market share, detailed healthcare cro services market segments, market trends and opportunities, and any further data you may need to thrive in the healthcare cro services industry. This healthcare cro services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Healthcare CRO services refer to the outsourced expertise and support provided to the pharmaceutical, biotechnology, and medical device industries by specialized organizations. These companies assist with a range of research-related tasks, including data management, conducting clinical trials, and preparing submissions for regulatory authorities.

The primary categories of healthcare CRO services include early-phase development, clinical development services, laboratory services, and consulting services. Early-phase development represents the initial stage of a project, focusing on the investigation, testing, and validation of hypotheses to establish a foundation for subsequent development. These services are applied across therapeutic areas such as oncology, CNS disorders, cardiovascular disease, metabolic disease, infectious diseases, and diabetes, and are utilized by pharmaceutical companies, medical device manufacturers, and academic institutions.

The healthcare CRO services market includes revenues earned by entities by providing services such as discovery studies, pre-clinical services, analytical testing, and related pharmacovigilance and drug safety, data management, and biostatistics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.